Home | Welcome to Contract Pharma   
Last Updated Sunday, May 24 2015


MethylGene Makes Management Changes

Published March 15, 2013
Jeffrey M. Besterman, Ph.D., has been appointed executive vice president of R&D and chief scientific officer at MethylGene, Inc. Joe Walewicz, vice president of business and corporate development, and Klaus B. Kepper, vice president finance and chief financial officer, will be leaving the company.
Dr. Charles Baum, chief executive officer, will take over Dr. Besterman’s responsibilities and Mark Gergen, chief operating officer has assumed the responsibilities of Mr. Kepper and Mr. Walewicz. 
"I want to personally thank Klaus, Jeff and Joe for their contributions to MethylGene," said Dr. Baum. “We wish them the best in their future pursuits.”

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On